<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290251</url>
  </required_header>
  <id_info>
    <org_study_id>060090</org_study_id>
    <secondary_id>1ZIAHD000637-17</secondary_id>
    <secondary_id>06-CH-0090</secondary_id>
    <nct_id>NCT00290251</nct_id>
  </id_info>
  <brief_title>Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914</brief_title>
  <official_title>Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine
      fibroids in pre-menopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine leiomyomata (fibroids) are a common benign tumor of the uterine muscle in
      pre-menopausal women that may cause bleeding, pelvic pain and pressure. Because fibroids grow
      in the presence of estrogen, medical therapies that decrease estrogen levels (like
      Gonadotropin releasing hormone,GnRH analog) cause fibroids to shrink and so may relieve
      symptoms. However, such medication can only be given short-term and has inconvenient side
      effects such as hot-flashes. Thus, many women with symptomatic fibroids choose to have them
      removed surgically, either individually or by removing the uterus via hysterectomy.

      Women between 25 and 50 years of age who have regular menstrual cycles and a history of
      uterine fibroids that cause heavy bleeding, pressure, or pain may be eligible for this study.
      Candidates are screened with a medical history and physical examination, including breast and
      pelvic examination, blood and urine tests, a quality-of-life questionnaire, and a home urine
      test for leuteinizing hormone (LH) surge. They are given a diary to record the LH surge, days
      of vaginal spotting or bleeding, and symptoms. Participation includes the following:

      Baseline Studies (First Menstrual Cycle)

        -  Magnetic resonance imaging (MRI): The subject lies in the MRI scanner, a narrow cylinder
           with a strong magnetic field, for imaging the uterus.

        -  Saline hysterosonogram: This is an ultrasound examination of the uterus. A speculum is
           placed in the vagina and a small amount of liquid is inserted into the uterus. A probe
           is then inserted into the vagina. The probe emits and receives sound waves that are used
           to visualize the fibroids and surrounding structures.

      Study Drug Phase (Second through Fourth Menstrual Cycles)

        -  Subjects are randomly assigned to take ulipristal acetate or placebo (inactive compound)
           once a day by mouth on an empty stomach for three menstrual cycles or up to 102 days if
           menstrual cycles are irregular or stop.

        -  Pregnancy test on first or second day of every menstrual cycle.

        -  Blood tests every 2 weeks to measure effects of study medication on hormones, blood
           count, blood chemistries and liver function.

        -  24-hour urine collections three times during the study, about once a month, to measure
           cortisol and check adrenal gland function.

        -  Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.

        -  Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
           fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for
           three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.

        -  Pregnancy test on first or second day of every menstrual cycle.

        -  Blood tests every 2 weeks to measure effects of study medication on hormones, blood
           count, blood chemistries and liver function.

        -  24-hour urine collections three times during the study, about once a month, to measure
           cortisol and check adrenal gland function.

        -  Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.

        -  Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
           fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for
           three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.

        -  Pregnancy test on first or second day of every menstrual cycle.

        -  Blood tests every 2 weeks to measure effects of study medication on hormones, blood
           count, blood chemistries and liver function.

        -  24-hour urine collections three times during the study, about once a month, to measure
           cortisol and check adrenal gland function.

        -  Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.

        -  Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the
           fibroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shrinkage of Fibroids - Size of Fibroids</measure>
    <time_frame>3 months (baseline to end of treatment)</time_frame>
    <description>The primary outcome, fibroid volume, was calculated by an ellipsoid formula (Ï€/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months (Baseline to end of treatment 1)</time_frame>
    <description>The short form-36 (SF-36)and Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaires were given before and at treatment end with scales of 0 - 100. SF-36 scales = mental and physical well-being. The UFS subscales are symptom severity, concern, activities, energy and mood, control, self-consciousness, sexual functioning compiled into an overall QOL score. Higher results indicate better QOL on all but symptom severity (higher = worse). The change in scores from baseline to end of treatment was calculated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>ulipristal acetate -20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ulipristal acetate - 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken daily for three menstrual cycles or up to 102 days in each study phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulipristal acetate</intervention_name>
    <description>ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic</description>
    <arm_group_label>ulipristal acetate -20 mg</arm_group_label>
    <other_name>VA2914; CDB-2914</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulipristal acetate</intervention_name>
    <description>10 mg given daily for three menstrual cycles or 90 - 102 days</description>
    <arm_group_label>ulipristal acetate - 10 mg</arm_group_label>
    <other_name>VA2914; CDB2914</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo given once daily for 3 menstrual cycles or 90 - 102 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Female gender-to evaluate effects in the target population for clinical trials.

          -  History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as
             defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin:

          -  Excessive uterine bleeding will be evidenced by either of the following-profuse
             bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or
             anemia due to acute or chronic blood loss;

        OR

          -  Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower
             abdominal or low back pressure or bladder pressure with urinary frequency not due to
             urinary tract infection.

          -  Uterine leiomyoma(ta) of at least 2 cm size.

          -  In good health. Chronic medication use is acceptable except for glucocorticoid use.
             Other chronic medication use may be acceptable at the discretion of the research team.
             Interval use of over-the-counter drugs is acceptable but must be recorded.

          -  Menstrual cycles of 24 - 35 days.

          -  Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered
             to improve red blood cell counts.

          -  Willing and able to comply with study requirements.

          -  Age 25 to 50.

          -  Using mechanical (condoms, diaphragms) sterilization or abstinence methods of
             contraception for the duration of the study.

          -  Negative urine pregnancy test.

          -  Body mass index (BMI) less than or equal to 33, if a surgical candidate or less than
             or equal to 35, if not a surgical candidate.

          -  Creatinine less than 1.3 mg/dL.

          -  Liver function tests within 130% of upper limit.

          -  If interested in hysterectomy, no desire for fertility.

        EXCLUSION CRITERIA:

          -  Significant abnormalities in the history, physical or laboratory examination.

          -  Pregnancy.

          -  Lactation.

          -  Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year.

          -  Unexplained vaginal bleeding.

          -  History of malignancy within the past 5 years.

          -  Use of estrogen or progesterone-containing compounds, such as oral contraceptives and
             hormone replacement therapy, within 8 weeks of study entry, including transdermal,
             injectable, vaginal and oral preparations.

          -  Use of agents known to induce hepatic P450 enzymes; use of imidazoles.

          -  Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that
             affect menstrual cyclicity.

          -  Follicle stimulating hormone (FSH) greater than 20 IU/mL.

          -  Untreated cervical dysplasia.

          -  Need for interval use of narcotics.

          -  Abnormal adnexal/ovarian mass.

          -  Use of herbal medication having estrogenic or antiestrogenic effects within the past 3
             months.

          -  Contradiction to anesthesia, for women planning surgery.

          -  Genetic causes of leiomyomata.

          -  Previous participation in the study.

          -  Known recent rapid growth of fibroids, defined as a doubling in size in six months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynnette K Nieman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NICHD, NIH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20891</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2006-CH-0090.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol. 1992 Jul;167(1):60-5.</citation>
    <PMID>1442957</PMID>
  </reference>
  <reference>
    <citation>Burroughs KD, Howe SR, Okubo Y, Fuchs-Young R, LeRoith D, Walker CL. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol. 2002 Jan;172(1):83-93.</citation>
    <PMID>11786376</PMID>
  </reference>
  <reference>
    <citation>Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129-56. Review.</citation>
    <PMID>9046951</PMID>
  </reference>
  <reference>
    <citation>Levens ED, Wesley R, Premkumar A, Blocker W, Nieman LK. Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care. Am J Obstet Gynecol. 2009 May;200(5):537.e1-7. doi: 10.1016/j.ajog.2008.12.037. Epub 2009 Mar 9.</citation>
    <PMID>19268886</PMID>
  </reference>
  <reference>
    <citation>Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011 Feb;95(2):767-72.e1-2. doi: 10.1016/j.fertnstert.2010.09.059. Epub 2010 Nov 5.</citation>
    <PMID>21055739</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>October 28, 2011</results_first_submitted>
  <results_first_submitted_qc>November 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2012</results_first_posted>
  <last_update_submitted>November 14, 2012</last_update_submitted>
  <last_update_submitted_qc>November 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrium</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Fibroid</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Seventy-two women were screened for eligibility before being randomized to treatment 1. Of these only 42 were eligible to continue in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ulipristal Acetate - 20 mg</title>
          <description>Women received ulipristal acetate at a daily dose of 20 mg for 90 - 102 days or three menstrual cycles.</description>
        </group>
        <group group_id="P2">
          <title>Ulipristal Acetate- 10 mg</title>
          <description>Women received ulipristal acetate at a daily dose of 10 mg for 90 - 102 days or three menstrual cycles.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (PLC)</title>
          <description>Women received placebo capsules for 90 - 102 days or three menstrual cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 1 (Months 1 - 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>headache</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of body experience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment 2 (Months 4 - 6)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">2 crossed over from placebo; others in treatment 1 PLC or ulipristal acetate 20 did not continue</participants>
                <participants group_id="P2" count="5">2 crossed over from placebo; others in treatment 1 PLC or ulipristal acetate 10 grp did not continue</participants>
                <participants group_id="P3" count="0">Women were randomized from PLC to ulipristal acetate or continued same dose ulipristal acetate</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Elective Extension (to 12 Months no Rx)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">Extension study was elective and observational only; treatment arm given as last study drug group</participants>
                <participants group_id="P2" count="3">Extension study was elective and observational only; treatment arm given as last study drug group</participants>
                <participants group_id="P3" count="5">Extension study was elective and observational only; treatment arm given as last study drug group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eligible Women</title>
          <description>All women who consented and were eligible</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Shrinkage of Fibroids - Size of Fibroids</title>
        <description>The primary outcome, fibroid volume, was calculated by an ellipsoid formula (Ï€/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.</description>
        <time_frame>3 months (baseline to end of treatment)</time_frame>
        <population>Per protocol, including women with two MRIs regardless of whether they took all study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate -20mg</title>
            <description>Women received ulipristal acetate at 20 mg/day for 90 - 102 days or three menstrual cycles.</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate - 10 mg</title>
            <description>Women received ulipristal acetate at 10 mg/day for 90 - 102 days or three menstrual cycles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Women received placebo capsules for 90 - 102 days or three menstrual cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Shrinkage of Fibroids - Size of Fibroids</title>
          <description>The primary outcome, fibroid volume, was calculated by an ellipsoid formula (Ï€/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.</description>
          <population>Per protocol, including women with two MRIs regardless of whether they took all study medication</population>
          <units>logcm3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.07"/>
                    <measurement group_id="O2" value="-0.18" spread="0.08"/>
                    <measurement group_id="O3" value="0.07" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ulipristal acetate groups one and two were first compared and found to be similar, so they were combined into a single treatment group for comparison to placebo group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.01</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Performed on log-transformed delta change</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>The short form-36 (SF-36)and Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaires were given before and at treatment end with scales of 0 - 100. SF-36 scales = mental and physical well-being. The UFS subscales are symptom severity, concern, activities, energy and mood, control, self-consciousness, sexual functioning compiled into an overall QOL score. Higher results indicate better QOL on all but symptom severity (higher = worse). The change in scores from baseline to end of treatment was calculated.</description>
        <time_frame>3 months (Baseline to end of treatment 1)</time_frame>
        <population>All completers received a questionnaire at the end of the three-month study. One woman in the placebo group did not complete the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate -10 and 20mg</title>
            <description>Women received ulipristal acetate at a daily dose of 10 or 20 mg for 90 - 102 days or three menstrual cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women received placebo capsules for 90 - 102 days or three menstrual cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>The short form-36 (SF-36)and Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaires were given before and at treatment end with scales of 0 - 100. SF-36 scales = mental and physical well-being. The UFS subscales are symptom severity, concern, activities, energy and mood, control, self-consciousness, sexual functioning compiled into an overall QOL score. Higher results indicate better QOL on all but symptom severity (higher = worse). The change in scores from baseline to end of treatment was calculated.</description>
          <population>All completers received a questionnaire at the end of the three-month study. One woman in the placebo group did not complete the questionnaire.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 Physical Component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.2"/>
                    <measurement group_id="O2" value="-1.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Mental Component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.5"/>
                    <measurement group_id="O2" value="-2.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS Symptom Severity Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="4.2"/>
                    <measurement group_id="O2" value="-4.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS Overall health related quality of life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="3.6"/>
                    <measurement group_id="O2" value="8.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS Concern subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="4.5"/>
                    <measurement group_id="O2" value="12.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS Energy/mood subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="3.7"/>
                    <measurement group_id="O2" value="3.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS Control subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="4.3"/>
                    <measurement group_id="O2" value="9.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS self-conscious subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="4.7"/>
                    <measurement group_id="O2" value="15.8" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS sexual function subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="5.5"/>
                    <measurement group_id="O2" value="18.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS activities subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" spread="4.4"/>
                    <measurement group_id="O2" value="56.1" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFS composite bleeding subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No sample size calculation was made.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <p_value_desc>The Delta of scores from treatment end to baseline was used to compare by ANOVA.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjustment for age</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment periods including cross-over treatments with active compound. The number at risk is larger than the starting number in the treatment groups because of crossover additions to the treatment groups</time_frame>
      <desc>Women recorded specific adverse events on a calendar; there was also a write-in field. The percentage of days in which any event was experienced was calculated for baseline and treatment. The difference between the two was considered the &quot;true&quot; incidence of events.</desc>
      <group_list>
        <group group_id="E1">
          <title>CDB-2914 -20mg</title>
          <description>Women received CDB-2914 at a daily dose of 20 mg for 90 - 102 days or three menstrual cycles.</description>
        </group>
        <group group_id="E2">
          <title>CDB-2914 - 10 mg</title>
          <description>Women received CDB-2914 at a daily dose of 10 mg for 90 - 102 days or three menstrual cycles.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Women received placebo capsules for 90 - 102 days or three menstrual cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <description>Self-reported via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="61" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Decreased appetitie</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="12" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="120" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="34" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <description>Self-assessed via calendar</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="74" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="28" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="19" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="23" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="21" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal cramps</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="18" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Leg swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>self-assessed via calendar and write-in option</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="47" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>self-assessed via calendar using write-in option</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="62" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Depersonalization</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Out of body experience</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="76" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="19" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Calf or Thigh pain</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="28" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>self-assessed by calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="21" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood changes</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="15" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="95" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="37" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="42" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-menses Vaginal Bleeding</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="21" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="129" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <description>self-assessed via calendar</description>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="91" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="19" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <description>Self-reported via calendar</description>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="81" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <description>Self-reported via calendar</description>
                <counts group_id="E1" events="105" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="92" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="11" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynnette Nieman MD</name_or_title>
      <organization>NICHD, NIH</organization>
      <phone>301-496-8935</phone>
      <email>NiemanL@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

